USPTO serial 88521914
POLYTAXEL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 28, 2022
- Examiner
- VALLILLO, MELISSA C
- Law office
- TMEG LAW OFFICE 105
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with POLYTAXEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of pancreatic tumors; pharmaceutical agents for the treatment of disorders in sensory organs; thyroid and para-thyroid hormone preparations; medicinal tonics for the treatment of pancreatic tumors; oral contraceptive pills; antiemetics; local anesthetics; bronchodilating preparations; anti-cough drops; androgen preparations; pituitary hormone preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents for use in regulating metabolism; vaccines against flu; chilblain preparations; pharmaceutical preparations for headache; anaesthetics; pharmaceutical for use in the treating disorders of the peripheral nervous system; pharmaceutical preparations for immunity adjustment; nutritive substances for microorganisms for medical purposes; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations for treating disorders of the urogenital organs; vitamin preparations; pharmaceutical preparations for the treatment of bone diseases; anti-inflammatory and antipyretic preparations; pharmaceutical agents for treating disorders of the digestive organs; pharmaceutical preparations for the treatment of cardiovascular disorders; nervines; ophthalmic preparations; allergy medications; chemicopharmaceutical preparations for the treatment of pancreatic disorders; medicines for the treatment of gastrointestinal diseases; mineral injection preparations featuring vitamin supplements for medical purposes; antioxidants for medical purposes; haematogen; pharmaceutical preparations for tumor treatment; multivitamin preparations; suppositories; pharmaceutical preparations for use in the treatment of disorders of the central nervous system; pharmaceutical preparations for diagnosis of cancer; sedatives; analgesics; vaginal washes for medical purposes; pharmaceutical preparations for treating asthma; medicines for treating tooth pain; hemorrhoid preparations; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; vaccines against pneumococcal infections; dermatological pharmaceutical products; contraceptive preparations; antihypertensives; anti-uric preparations; anti-diabetic pharmaceuticals; pharmaceutical preparations for treatment of hemorrhoids; antibiotic preparations; antibiotics; anti-cancer preparations; anti-cancer treatment supplements; antidepressants; anticoagulants; antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; febrifuges; vasoconstrictors; hypoglycemic agents; blood solvent being preparations for treating blood disorders; pharmaceutical preparations for treating disorders of the respiratory organs; respiratory stimulant preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for treating respiratory diseases and asthma; mixed vitamin preparations; preparations for the treatment of burns; disinfectants for chemical toilets; chemotherapeutics; preparations for treatment of hepatitis; preparations for treating colds; preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of osteoporosis; preparations for the treatment of osteoporosis; injectable pharmaceuticals for treatment of anaphylactic reactions; pharmaceutical preparations for treating halitosis; nausea treatment preparations; antiulcerants; pharmaceutical preparations for the treatment of musculoskeletal disorders; preparations for the treatment of muscle fatigue; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for the treatment of rhinitis; pharmaceutical products for the treatment of bone diseases; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; pharmaceutical preparations for the treatment of cancerous cells; medicines for treating intestinal disorders; cardiovascular treatment preparations; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for treating allergies; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; medicated preparations for the treatment of mouth disorders; transdermal patches for medical treatment of nausea; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of gout; drug delivery agents in the form of dissolvable films, coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 18, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 18, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 18, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 18, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 18, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 28, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 28, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 12, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 12, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 11, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 5, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 28, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 23, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 21, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 14, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 7, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 5, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 28, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 30, 2021 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 13, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 13, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 13, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 13, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 13, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 9, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 19, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 17, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 17, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 17, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 16, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 9, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 26, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 26, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 10, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 10, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 10, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 7, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 25, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 22, 2019 | NWAP | NEW APPLICATION ENTERED | — |